Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on VERTEX PHARMACEUTICALS
01/19 VERTEX PHARMACEUTICALS : Receives EU Approval for ORKAMBI® lumacaftor/ivacaftor ..
01/11 VERTEX PHARMACEUTICALS : Announces Upcoming Presentation at the J.P. Morgan Heal..
01/11 VERTEX PHARMACEUTICALS : Receives EU Approval for ORKAMBI in Children with Cysti..
01/10 VERTEX PHARMACEUTICALS : Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor..
01/05 VERTEX PHARMACEUTICALS : CRISPR raises $113.8M in follow-on
01/04 VERTEX PHARMACEUTICALS : New Data from Vertex Pharmaceuticals Illuminate Finding..
01/03 VERTEX PHARMACEUTICALS : Announces Upcoming Presentation at the J.P. Morgan Heal..
01/03 NASDAQ 100 MOVERS : Intc, expe
2017 VERTEX PHARMACEUTICALS : and CRISPR Therapeutics to Co-Develop and Co-Commercial..
2017 CRISPR THERAPEUTICS AG (NASDAQ : CRSP) Files An 8-K Entry into a Material Defini..
2017 VERTEX PHARMACEUTICALS : CF Children, Ages 1-2, Safely Treated with Kalydeco
2017 VERTEX PHARMACEUTICALS : and CRISPR Therapeutics to Co-Develop and Co-Commercial..
2017 VERTEX PHARMACEUTICALS : makes first pick in CRISPR collaboration
2017 NASDAQ 100 MOVERS : Orly, bmrn
2017 VERTEX PHARMACEUTICALS : Announces Positive Results from Open-Label Phase 3 Stud..
2017 Tax-loss selling to pressure 2017's losers in December
2017 VERTEX PHARMACEUTICALS : Announces Positive Results from Open-Label Phase 3 Stud..
2017 VERTEX PHARMACEUTICALS : Receives CHMP Positive Opinion for ORKAMBI® lumacaftor/..
2017 S&P 500 MOVERS : Vrtx, dlph
2017 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
2017 Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Pe..
2017 Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
2017 VERTEX PHARMACEUTICALS : Earnings Review and Free Research Report: Vertex’s Reve..
2017 VERTEX PHARMACEUTICALS : Latest Trial Data on Vertex CF Therapies and New Combos..
2017 VERTEX PHARMACEUTICALS : Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor..
2017 VERTEX PHARMACEUTICALS : to Present at the Credit Suisse Healthcare Conference o..
2017 VERTEX PHARMACEUTICALS : Announces New $750,000 Program to Support the Work of t..
2017 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
2017 VERTEX PHARMACEUTICALS : Phase 3 Studies of the Tezacaftor, Ivacaftor Combinatio..
2017 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
2017 VERTEX PHARMACEUTICALS : Phase 3 Studies of the Tezacaftor/Ivacaftor Combination..
2017 VERTEX PHARMACEUTICALS : Announces New $750,000 Program to Support the Work of t..
2017 VERTEX PHARMACEUTICALS : to Present at the Credit Suisse Healthcare Conference o..
2017 VERTEX PHARMACEUTICALS : Doubles Scholarship Program to Support the Academic and..
2017 VERTEX PHARMACEUTICALS : Announces New $750,000 Program to Support the Work of t..
2017 VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
2017 VERTEX PHARMACEUTICALS : MA Completion of Acquisition or Disposition of Assets (..
2017 VERTEX PHARMACEUTICALS : Announces 10-Year, $500 Million Corporate Giving Commit..
2017 VERTEX PHARMACEUTICALS : to Announce Third Quarter 2017 Financial Results on Oct..
2017 VERTEX PHARMACEUTICALS : Patent Issued for Method for Measuring ATR Inhibition M..
2017 VERTEX PHARMACEUTICALS : reports 3Q loss
2017 VERTEX PHARMACEUTICALS INC / MA : Completion of Acquisition or Disposition of As..
2017 VERTEX PHARMACEUTICALS : Reports Third-Quarter 2017 Financial Results
2017 VERTEX PHARMACEUTICALS : Doubles Scholarship Program to Support the Academic and..
2017 VERTEX PHARMACEUTICALS : Doubles Scholarship Program to Support the Academic and..
2017 VERTEX PHARMACEUTICALS : Announces 10 Year $500 Million Corporate Giving Commitm..
2017 VERTEX PHARMACEUTICALS : to Announce Third Quarter 2017 Financial Results on Oct..
2017 VERTEX PHARMACEUTICALS : Announces 10-Year, $500 Million Corporate Giving Commit..
2017 VERTEX PHARMACEUTICALS : to Announce Third Quarter 2017 Financial Results on Oct..
2017 NASDAQ 100 MOVERS : Jbht, wynn
2017 VERTEX PHARMACEUTICALS : Report Summarizes Drug Metabolism and Disposition Study..
2017 VERTEX PHARMACEUTICALS : New Tuberculosis Study Findings Have Been Reported by I..
2017 VERTEX PHARMACEUTICALS : Provo girl finds a caring 'team of sisters' in BYU soft..
2017 VERTEX PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series on..
2017 VERTEX PHARMACEUTICALS : Announces Upcoming Presentations of Data at 2017 North ..
2017 VERTEX PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series on..
2017 VERTEX PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series on..
2017 VERTEX PHARMACEUTICALS : Announces Upcoming Presentations of Data at 2017 North ..
2017 VERTEX PHARMACEUTICALS : Announces Upcoming Presentations of Data at 2017 North ..
2017 VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Healthcare Conference ..
2017 VERTEX PHARMACEUTICALS : Appoints Tom Graney as Senior Vice President and Chief ..
2017 VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Healthcare Conference ..
2017 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Departure of Directors..
2017 VERTEX PHARMACEUTICALS INC / MA : Change in Directors or Principal Officers (for..
2017 VERTEX PHARMACEUTICALS : Appoints Tom Graney as Senior Vice President and Chief ..
2017 VERTEX PHARMACEUTICALS : Announces Acceptance of its Applications for Review of ..
2017 VERTEX PHARMACEUTICALS : Announces Acceptance of its Applications for Review of ..
2017 BIOTECH MOVERS : Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) and Vertex Pharmaceu..
2017 VERTEX PHARMACEUTICALS : Announces Acceptance of its Applications for Review of ..
2017 NASDAQ 100 MOVERS : Myl, vrtx
2017 RESEARCHERS FROM CONCERT PHARMACEUTI : ...
2017 VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® ivacaftor for More Than 600 Peop..
2017 VERTEX PHARMACEUTICALS : Breakfast Technical Briefing on Biotech Stocks -- Sarep..
2017 DATA ON GASTROENTEROLOGY REPORTED BY : Impact of Measured,...
2017 VERTEX PHARMACEUTICALS : and Concert Pharmaceuticals Complete Asset Purchase Agr..
1  2  3  4  5  6  7  8  9Next
Financials ($)
Sales 2017 2 334 M
EBIT 2017 538 M
Net income 2017 293 M
Finance 2017 932 M
Yield 2017 -
P/E ratio 2017 157,70
P/E ratio 2018 87,36
EV / Sales 2017 16,7x
EV / Sales 2018 14,0x
Capitalization 39 951 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 183 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS4.76%39 951
GILEAD SCIENCES14.10%105 754
REGENERON PHARMACEUTICALS-0.50%39 917
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284
BLUEBIRD BIO INC2.25%8 064